Nivalis Therapeutics, Inc. (NASDAQ: NVLS) today announced the expansion of their clinical development plan for N91115, the Company’s lead investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE